BJDX (Bluejay Diagnostics, Inc. Common Stock) Stock Analysis - AI Report
Bluejay Diagnostics, Inc. Common Stock (BJDX) is a publicly traded Healthcare sector company. As of May 21, 2026, BJDX trades at $1.70 with a market cap of $1.78M and a P/E ratio of -0.11. BJDX moved +0.00% today. Year to date, BJDX is -32.95%; over the trailing twelve months it is -76.73%. Its 52-week range spans $1.62 to $49.80. Rallies surfaces BJDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on BJDX?
Rallies AI research for BJDX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Wurth Douglas Clark bought 12.50K (~$25.00K) on Mar 14, 2026.
Dey Indranil bought 12.50K (~$25.00K) on Mar 14, 2026.
CHASE DONALD R bought 12.50K (~$25.00K) on Mar 14, 2026.
BJDX Analyst Consensus
BJDX analyst coverage data. Average price target: $0.00.
Common questions about BJDX
What is the AI research view on BJDX?
Rallies AI research for BJDX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for BJDX?
Rallies AI research for BJDX combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is BJDX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BJDX. It does not provide personalized investment advice.